Table 9 action profile of human insulin and human insulin analogs
From: Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society
Human Insulins | Insulin Type | Onset | Action peak | Duration of action |
|---|---|---|---|---|
Rapid-acting insulin analogs | Glulisine (Apidra®) | <5-15 minutes | 1 hour | 4 hours |
Lispro (Humalog®) | <15 minutes | 0.5-1.5 hour | 2-4 hours | |
Aspart (NovoRapid®) | 5-10 minutes | 1-3 hours | 3-5 hours | |
Short acting insulin | Regular (Novolin® R, Humulin® R) | 30-60 minutes | 2-3 hours | 3-6 hours |
Intermediate acting insulin | NPH (Novolin® N Humulin® N) | 2-4 hours | 4-10 hours | 10-16 hours |
Long-acting insulin analogs | Glargine (Lantus®) | 1-2 hours | None | Up to 24 hours |
Detemir (Levemir®) | 1-2 hours | None | Up to 24 hours |